Disappointing news for Australian company Sirtex Medical with the results of its 459-patient SARAH study confirming no survival benefit from use of its SIR-Spheres Y-90 resin microspheres over Bayer's PBS-listed NEXAVAR (sorafenib). …
Latest Video
New Stories
-
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News -
PYC Therapeutics names Thomas Ulmer as new chief financial officer
July 8, 2026 - - Australian Biotech -
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 - - Latest News -
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 - - Latest News -
'But I've said it's really important that these two drugs stay on the PBS'
July 7, 2026 - - Latest News -
Just another attempt to create a new excuse to avoid a meaningful discussion about change
July 7, 2026 - - Latest News -
Australia must keep development manufacturing and jobs here to secure health and economic benefits
July 7, 2026 - - Latest News